Back

PD-L1-linked spatial decoupling of tumour-immune interactions in EBV-positive DLBCL

Kunstner, A.; Kuemmel, M.; Faehnrich, A.; Derer, S.; Raschdorf, A.; Witte, H. M.; Maluje, Y.; Faerber, B.; Roesner, T.; Michelson, L.; Stiller, F.; Merz, M. M.; Bernard, V.; Stoelting, S.; Kolbe, D.; Peter, W.; Merz, H.; von Bubnoff, N.; Feller, A. C.; Busch, H.; Lohneis, P.; Gebauer, N.

2026-07-04 genetic and genomic medicine
10.64898/2026.07.02.26357123 medRxiv
Show abstract

EBV-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma enriched in elderly patients, in which PD-L1 genomic gains cooperate with viral signalling to promote immune escape. However, the spatial mechanisms by which PD-L1 reshapes the tumour microenvironment remain unresolved. Here, we integrate genomic profiling with spatial transcriptomics, spatial proteomics, and single-cell RNA sequencing to resolve the tumour-immune architecture of EBV-positive DLBCL. PD-L1 gain tumours exhibit a striking decoupling of immune proximity and immune engagement: T cells accumulate in close proximity to tumour cells yet direct tumour-immune contact is largely absent. Tumour boundaries are enriched for cancer-associated fibroblasts and display transcriptional signatures of metabolic immune suppression, while tumour-proximal T cells exhibit pronounced exhaustion. Together, these findings reveal a PD-L1 driven spatial immune evasion architecture that permits immune infiltration while enforcing multilayered suppression through fibroblast-mediated exclusion, metabolic constraint, and T-cell dysfunction, ultimately preventing effective anti-tumour immunity in EBV-positive DLBCL.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.